DUBLIN, Nov. 09, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/l26l79/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2015-2019" report to their offering.
The global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.
This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The report includes a discussion of the key vendors operating in this market.
Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.
R&D in the market is rising in terms of the increasing collaborations between companies and the increase in mergers and acquisitions. For instance, in January 2014, Sanofi and Alnylam signed an agreement for the development of treatment therapies for rare genetic diseases.
According to the report, Biologic therapeutics are expensive and cannot be afforded by all, but the reimbursement of diagnostic kits and biologic drugs is expected to drive the market during the forecast period.
Further, the report states that competition is a major challenge for the market and varies depending on the disease. However, the market competition is negligible for biologics such as Fabrazyme, which is the only approved therapy in the US for the treatment of Fabry disease.
- F. Hoffmann-La Roche
- Novo Nordisk
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Market segmentation by type of molecules
Part 07: Global protein therapeutics market
Part 08: Global vaccines market
Part 09: Global cell therapy market
Part 10: Geographical segmentation
Part 11: Market drivers
Part 12: Impact of drivers
Part 13: Market challenges
Part 14: Impact of drivers and challenges
Part 15: Market trends
Part 16: Vendor landscape
Part 17: Key vendor analysis
Part 18: Appendix
For more information visit http://www.researchandmarkets.com/research/l26l79/global_biologic
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets